Lv4
418 积分 2024-05-28 加入
CD19-directed CAR T cells gain traction
1个月前
已完结
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia
1个月前
已完结
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3
1个月前
已完结
Five-Year Update of the Phase 2 ELARA Trial of Tisagenlecleucel in Patients (pts) with relapsed/refractory Follicular Lymphoma (r/r FL)
1个月前
已关闭
Talicabtagene Autoleucel: First Approval
1个月前
已完结
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
1个月前
已完结
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
1个月前
已完结
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
1个月前
已完结
B-Cell Maturation Protein, Which Binds the Tumor Necrosis Factor Family Members BAFF and APRIL, Is Dispensable for Humoral Immune Responses
1个月前
已关闭
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
1个月前
已完结
皖公网安备34019202002308
